Jaguar Health Subsidiary Napo Pharmaceuticals Launches New Website for Mytesi, Napo’s FDA-Approved, First-in-Class Anti-Secretory Human Prescription Drug
Site Provides Information and Resources for Consumers as Well as HIV Physicians, Gastroenterologists and Other Healthcare Professionals
Mytesi® is the first and only antidiarrheal approved by the
A new “Healthcare Professional” area on the site provides Mytesi®-related scientific and clinical trial data for HIV physicians as well as gastroenterologists—many of whom see large numbers of PLWHA.
“As someone living with HIV, the internet is my go-to for anything
related to HIV. For newly diagnosed patients, having this information
online, presented in a way that is consumable by a non-medical
professional, is even more important, as the web is typically the first
place one goes to when needing more information. A lot of people feel
more comfortable searching on their computer verses talking to a doctor
upfront, so it’s critical that the right information is out there,
available for anyone who's searching for it,” stated
Mytesi® works by normalizing water flow in the intestines, which is different from other antidiarrheals, and, because Mytesi® is not absorbed into the blood stream, it has few side effects and no drug-drug interactions. Mytesi® is widely available, and people living with HIV/AIDS who are tired of planning their life around diarrhea can ask their provider for a prescription for Mytesi®.
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
KCSA Strategic Communications
Garth Russell, 212-896-1250